Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prestige Consumer Healthcare (PBH) EBITDA (2016 - 2025)

Historic EBITDA for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $48.1 million.

  • Prestige Consumer Healthcare's EBITDA rose 138.81% to $48.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $196.4 million, marking a year-over-year decrease of 290.11%. This contributed to the annual value of $211.4 million for FY2025, which is 243.84% up from last year.
  • Prestige Consumer Healthcare's EBITDA amounted to $48.1 million in Q4 2025, which was up 138.81% from $42.9 million recorded in Q3 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's EBITDA peaked at $60.5 million during Q4 2023, and registered a low of -$242.6 million during Q1 2023.
  • Over the past 5 years, Prestige Consumer Healthcare's median EBITDA value was $50.6 million (recorded in 2021), while the average stood at $35.3 million.
  • Per our database at Business Quant, Prestige Consumer Healthcare's EBITDA plummeted by 53125.26% in 2023 and then skyrocketed by 11792.55% in 2024.
  • Over the past 5 years, Prestige Consumer Healthcare's EBITDA (Quarter) stood at $51.4 million in 2021, then rose by 14.57% to $58.9 million in 2022, then grew by 2.7% to $60.5 million in 2023, then decreased by 21.66% to $47.4 million in 2024, then grew by 1.39% to $48.1 million in 2025.
  • Its EBITDA stands at $48.1 million for Q4 2025, versus $42.9 million for Q3 2025 and $52.9 million for Q2 2025.